MatthewLee,FawziAbu Rous,AlainBorczuk,StephenLiu,ShirishGadgeel,BalazsHalmos
Targeting Oncogenic Driver Mutations in Lung Cancer
Targeting Oncogenic Driver Mutations in Lung Cancer
YOU SAVE £1.36
- Condition: Brand new
- UK Delivery times: Usually arrives within 2 - 3 working days
- UK Shipping: Fee starts at £2.39. Subject to product weight & dimension
Couldn't load pickup availability
Excellent- More about Targeting Oncogenic Driver Mutations in Lung Cancer
The recent advances in molecular diagnostic techniques have identified targetable alterations in non-small cell lung cancer (NSCLC), leading to a paradigm shift in precision oncology. This Element highlights the most clinically relevant oncogenic drivers, their management, and current advancements in treatment. It also examines the challenges in resistance to targeted therapies and diagnostic dilemmas.
Format: Paperback / softback
Length: 75 pages
Publication date: 02 February 2023
Publisher: Cambridge University Press
The recent breakthroughs in molecular diagnostic techniques have brought about a significant shift in the management of non-small cell lung cancer (NSCLC), ushering in an era of precision oncology. These advancements have identified targetable alterations, leading to a paradigm change in the treatment approach. This Element focuses on highlighting the most clinically relevant oncogenic drivers beyond EGFR, their management, and the latest advancements in treatment. It also delves into the challenges associated with resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver. Furthermore, it explores the future direction of NSCLC management and the potential for personalized and targeted therapies to revolutionize the field.
The recent advancements in molecular diagnostic techniques have revolutionized the management of non-small cell lung cancer (NSCLC). These breakthroughs have identified targetable alterations, leading to a paradigm shift in the treatment approach. This Element focuses on highlighting the most clinically relevant oncogenic drivers beyond EGFR, their management, and the latest advancements in treatment. It also delves into the challenges associated with resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver. Furthermore, it explores the future direction of NSCLC management and the potential for personalized and targeted therapies to revolutionize the field.
The recent breakthroughs in molecular diagnostic techniques have transformed the landscape of non-small cell lung cancer (NSCLC) management. These advancements have identified targetable alterations, leading to a paradigm shift in the treatment approach. This Element highlights the most clinically relevant oncogenic drivers beyond EGFR, their management, and the latest advancements in treatment. It also delves into the challenges associated with resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver. Furthermore, it explores the future direction of NSCLC management and the potential for personalized and targeted therapies to revolutionize the field.
The recent advancements in molecular diagnostic techniques have revolutionized the management of non-small cell lung cancer (NSCLC). These breakthroughs have identified targetable alterations, leading to a paradigm shift in the treatment approach. This Element focuses on highlighting the most clinically relevant oncogenic drivers beyond EGFR, their management, and the latest advancements in treatment. It also delves into the challenges associated with resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver. Furthermore, it explores the future direction of NSCLC management and the potential for personalized and targeted therapies to revolutionize the field.
ISBN-13: 9781009336130
This item can be found in:
UK and International shipping information
UK and International shipping information
UK Delivery and returns information:
- Delivery within 2 - 3 days when ordering in the UK.
- Shipping fee for UK customers from £2.39. Fully tracked shipping service available.
- Returns policy: Return within 30 days of receipt for full refund.
International deliveries:
Shulph Ink now ships to Australia, Belgium, Canada, France, Germany, Ireland, Italy, India, Luxembourg Saudi Arabia, Singapore, Spain, Netherlands, New Zealand, United Arab Emirates, United States of America.
- Delivery times: within 5 - 10 days for international orders.
- Shipping fee: charges vary for overseas orders. Only tracked services are available for most international orders. Some countries have untracked shipping options.
- Customs charges: If ordering to addresses outside the United Kingdom, you may or may not incur additional customs and duties fees during local delivery.
